Bacteremia caused by Staphylococcus aureus continues to be a common problem worldwide. Antimicrobial drug resistance in S.aureus arose early after the development of antimicrobial agents and continues to evolve. This resistance limits the potentially efficacious agents and results in frequent use of glycopeptides, such as vancomycin. The reliance on vancomycin causes difficulties because vancomycin has been shown to be less effective than isoxazolyl penicillins (e.g.,flucloxacillin) in treating severe infections caused by S.aureus. This may be one explanation for the higher death rate associated with bacteremia caused by MRSA, compared with that caused by MSSA. S. aureus remains a common cause of bloodstream infections of community onset; increasing numbers of these being caused by MRSA. Some of these infections are caused by hospital strains carried into the community by patients or healthcare workers, while others are caused by true community strains in patients who have had no recent healthcare contact. Certain population of patients have a significantly greater risk of invasive staphylococci infection than normal population; represented by those receiving hemodialysis, peritoneal dialysis, IV drug abusers, patients suffering from Diabetes Mellitus and alcohol abusers. S.aureus have developed resistance to virtually all antibiotic classes which include Aminoglycosides, Tetracyclines, Cotrimaxazole, Quinolones, and new Oxazolidinones. Methods for susceptible testing of MRSA include disk diffusion method, Broth dilution method, agar screen methods. This study helps us to have a clear knowledge about the risk factors associated with MRSA and the antibiotic sensitivity pattern of the organism which guides to formulate an empirical therapy for the patients with staphylococcal infections.